Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "GN - Glomerulonephritis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glomerulonephritis (GN), also known as glomerular nephritis, is a term used to refer to several kidney diseases (usually affecting both kidneys).
Traditional Chinese medicine for treating acute renal glomerulus nephritis
InactiveCN101129862ACompatibility is simpleLow costUrinary disorderPlant ingredientsDiseaseRenal glomerulus
Disclosed is a Chinese medicament for treating acute glomerular nephritis wherein the recipe includes astragalus root 20g, root of red rooted saliva 15g, cogongrass rhizome 40g, rhizome smilacis glabrae 100g, motherwort 20g, malt 30g, arctium fruit 10g, bletilla tuber 12g, kudzuvine root 8g, cordate houttuynia 10g, plantain seeds, polyporus umbellatus each 20g, alkanna tinctoria, eclipta, notoginseng each 30g, Achyranthes bidentatae 25g, sweet basil, ledebouriella root each 30g. The Chinese medicament has simplified recipe, easy preparing process and low price.
Owner:尹克山
Technique for preparing verbascoside with function of curing chronic glomerulonephritis in glutinous rehmannia leaf
InactiveCN101121740ANon-toxic and safeConducive to extensive clinical applicationEsterified saccharide compoundsSugar derivativesAcute toxicity testingDigitalis
The invention belongs to the technological field of the Chinese medicine, particularly relating to an extraction and separation processes of the active ingredients with the active function of treating the chronic glomerulonephritis. The mullein indican is the active compound researched and developed for many years in our research institute; the mullein indican is extracted, separated and refined from the digitalis leaf and is an active compound with the function of treating the chronic glomerulonephritis. The invention is the research result of many years held and developed by the Chinese Medicine Research Department of the Chinese Medicine Research Institute of China and is supported by the special fund of the Central Institute of the National Science and Technology Department; now the compound has been approved by the State Food and Drug Administration Bureau as the novel drug and the mechanism research of the treatment of the chronic nephritis has been completed; the pre-clinical research work includes the main pharmacodynamic experiment, the production technology experiment (including the industrialized extraction and separation processes), the quality control standard, the experiment of the affecting factors of the quality, the experiment of the long-term stability, the acute toxicity of the rat, the experiment of the long-term toxicity, the teratogenic and mutagenic experiment, the general pharmacological experiment, the pharmacokinetics experiment, and so on. The digitalis leaf is mainly produced in the Huaiqing area of the Henan province, and is also grown wild and cultivated in the Shaanxi, Hebei and other places of China.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.
Owner:MYRIAD RBM INC
Use of compounds from antrodia camphorata in manufacturing medicaments for treating kidney diseases
The present invention provides a use of compounds from Antrodia camphorata in manufacturing medicaments for treating kidney diseases, wherein the compounds is represented by formula (I):wherein R1 is a hydrogen atom or acetyl group, R2 iswherein the kidney disease is glomerulosclerosis or glomerulonephritis.
Owner:TSENG HUI LING
Short peptide, preparation method thereof, and applications of the short peptide in diagnosis or treatment of apoA-I related diseases
InactiveCN103570807AExtensive and important biological functionsStable function of apoA-IPeptide/protein ingredientsAntipyreticDiseaseGN - Glomerulonephritis
The invention discloses a short peptide, a preparation method thereof, and applications of the short pepetide in diagnosis or treatment of apoA-I related diseases. The sequence of the short peptide is Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2, wherein the amino acids used are all L-amino acids. An L-4F provided by the invention has functions similar to the apoA-I. In an accelerated arteriosclerotic mice lupus model, the L-4F is capable of reducing significantly double-stranded DNA resistance and oxidized-type PL resistance of IgG, improving degrees of proteinuria, glomerulonephritis and sclerotin reduction, increasing the amount of smooth muscle cells, reducing infiltration of macrophages, and reducing the level of inflammation chemotactic factors causing atherosclerosis at the same time. Accordingly, the L-4F treatment is a protective mechanism for lupus diseases, also has certain functions for rebuilding and fixing latent patches, and has a broad application prospect and high application value. The L-4F can be used for diagnosis and treatment of the apoA-I related diseases, and has high medicinal value. The L-4F is obtained by a solid-phase synthetic method with simple operation, and therefore the L-4F has a broad market prospect.
Owner:温州康成健康管理咨询有限公司 +1
Glomerulonephritis biomarkers
The present invention relates to methods of diagnosing glomerulonephritis (GN) in a patient, as well as methods of monitoring the progression of GN and / or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
Owner:MESO SCALE TECH LLC
Systems and methods for characterizing kidney diseases
InactiveUS7138229B2Microbiological testing/measurementDisease diagnosisNephrosisInterstitial Disease
Owner:RENOVAR
Medicament composition and preparation method for treating chronic glomerulonephritis
ActiveCN101632772AUrinary disorderLeech/worm material medical ingredientsCreatinine riseTotal protein
The invention discloses a medicament composition and a preparation method for treating chronic glomerulonephritis. The medicament composition comprises the components of raw material medicament based on portions by weight: 450 to 550 portions of milk veteh, 200 to 300 portions of angelica, 330 to 430 portions of yam, 200 to 300 portions of bupleurum, 250 to 350 portions of pyrrosia lingua, 250 to 350 portions of umbellate pore furgus and 50 to 100 portions of leech. The medicament composition has obvious effect on treating chronic glomerulonephritis, raises high cutting and low cutting of whole blood viscosity, blood plasma and red cell accumulation, reduces the levels of the total protein and the albumin of blood, raises the levels of the nitrogen and the creatinine of blood urea, improves blood haemorheology and raises urinary output by 3h and total urinary output.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL
Triazine dimers for the treatment of autoimmune diseases
Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.
Owner:PROMETIC PHARMA SMT LTD
Medicament for treating latent glomerulonephritis
ActiveCN103845617ASafe and effective treatmentNo significant differenceAnthropod material medical ingredientsFungi medical ingredientsTeucrium viscidumGN - Glomerulonephritis
The invention relates to a medicament for treating latent glomerulonephritis. The medicament is prepared from the following medicinal materials in parts by weight: 15 parts of aspidistra elatior, 3 parts of medicago falcate, 12 parts of common sesbania roots and leaves, 1 part of cotton eucommia, 20 parts of gurgeon stopper roots, 15 parts of clover fern, 20 parts of pteris cretica, 9 parts of needle juniper, 7 parts of stemflower brandisia, 2 parts of fungus-infected rice spikes, 20 parts of common edelweiss herb, 15 parts of caryopteris nepetaefolia, 9 parts of roots of hollyhock, 1 part of senecio nagensium, 5 parts of rigidleaf cymbidium fruits, 25 parts of wedelia chinensis, 3 parts of delavay meadowrue roots, 5 parts of swamp mahogany leaves, 12 parts of colysis elliptica, 1 part of argiope bruennichii, 1 part of teucrium viscidum, 2 parts of salvia prionitis and 15 parts of delavay greenleaves. Clinical experiments verify that the medicament can safely and effectively treat latent glomerulonephritis.
Owner:QIDONG CIYT XINZAO CASTING FACTORY
Treatment of lupus nephritis with anti-CD40L compounds
InactiveCN1247472AAvoid processPeptide/protein ingredientsAntipyreticGN - GlomerulonephritisDisease patient
Owner:BIOGEN INC
Compositions for the oral delivery of corticosteroids
Owner:CALLIDITAS THERAPEUTICS AB +1
Compositions and methods for diagnosing and treating kidney disorders in a canine
ActiveUS20120283129A1Reduce probabilityMicrobiological testing/measurementChemiluminescene/bioluminescenceFiltrationDecreased glomerular filtration rate
The present invention provides methods for: diagnosing of, devising and monitoring a treatment plan for, and monitoring the status of a kidney disorder characterized by an abnormal loss of renal function, renal failure, reduced glomerular filtration rate or glomerulonephritis, in a canine, wherein the kidney disorder is detectable by utilizing at least one relevant biomarker isolated and measured from a biological test sample taken from such canine. The invention additionally relates to compositions, reagents and kits for carrying out the specified methods.
Owner:HILLS PET NUTRITION INC
Capsule preparation for treating nephritis associated with hepatitis B and preparation method thereof
InactiveCN101933980AInhibition of replicationImproves kidney function in ratsDigestive systemAntiviralsDiseaseLiver and kidney
The invention relates to a capsule preparation for treating nephritis associated with hepatitis B and a preparation method thereof, belonging to the technical field of traditional Chinese medical preparations. The capsule preparation comprises an active component and a pharmaceutically acceptable carrier, wherein the active component is prepared from rhubarb and licorice. The preparation method of the capsule preparation comprises the following steps of: decocting the rhubarb and the licorice, mixing the decoctions, standing still, filtering and drying to obtain the active component; and mixing the active component with medical accessories, pelletizing and subpackaging in capsules to obtain the capsule preparation. The invention can restrict the replication of hepatitis B viruses, protect the liver, reduce enzyme, induce diuresis, reduce urinary protein, serum creatinine and urea, improve the renal function of a glomerulus nephritis rat and has the advantages of concurrent treatment of the liver and kidney, simultaneous treatment of the principal and secondary aspects of the diseases and symptomatic treatment.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Diacerein composition with good leaching property, and preparation and use thereof
Owner:安士制药(中山)有限公司
Nano vaccine of LAMP-2 epitope peptide and preparation method of nano vaccine
InactiveCN103550763AOvercoming the short half-lifeOvercome susceptibility to enzymatic hydrolysisPowder deliveryPharmaceutical non-active ingredientsVasculitisGN - Glomerulonephritis
The invention belongs to the field of biological medicines, and relates to a nano vaccine of LAMP-2 epitope peptide and a preparation method of the nano vaccine. The nano vaccine comprises an effective amount of polypeptide with the amino acid sequence as shown in SEQ IN DO:1, or a polypeptide mixture with the amino acid sequence as shown in SEQ IN DO:1 and SEQ IN DO:2, the nano vaccine can be prepared through the synergistic effect of a polylactic acid-glycolic acid copolymer with the polypeptide, and the nano vaccine can be applied to preparation of a nano vaccine for anti-neutrophile granulocyte cytoplasm antibody relevancy vasculitis and anti-LAMP-2 antibody relevancy pauci-immune complex crescent glomerulonephritis. Due to adoption of the nano vaccine, spontaneous immune response of autoantigen characteristics is eliminated, and immune response to other antigens is not interfere, and a novel method is provided for treatment on anti-neutrophile granulocyte cytoplasm antibody relevancy vasculitis and anti-LAMP-2 antibody relevancy pauci-immune complex crescent glomerulonephritis.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Use of prince feather and fleabane combination in preparing medicament for treating kidney disease
InactiveCN101306091AWeight increaseReduce contentSolution deliveryPill deliveryDiseaseRenal glomerulus
The invention discloses the application of the combination of prince feather and fleabane in preparing medicaments for curing kidney diseases. The kidney diseases include nephritis, nephropathy syndrome, chronic renal failure, diabetes, nephropathy, chronic glomerulonephritis and so on. The combination of prince feather and fleabane is prepared as follows: Chinese traditional medicaments, namely prince feather and fleabane, are combined; the combined prince feather and fleaban are extracted, or the prince feather and the fleabane are extracted separately. The invention provides a new medicinal use of the combination of prince feather and fleabane, namely the application of the combination in preparing medicaments for curing kidney diseases. Proven through animal experiments, the combination of the prince feather and the fleabane has true curative effect on cure of kidney diseases, and provides a new medicine for curing kidney diseases and a new option for sufferers.
Owner:GUIZHOU YIBAI PHARMA CO LTD
Chinese medicament for treating nephritis
InactiveCN102935203AImprove stabilityClinical trials are effectiveUrinary disorderPlant ingredientsPetrogale lateralis purpureicollisTreatment effect
The invention discloses a Chinese medicament for treating nephritis. The Chinese medicament is prepared from 200 to 300 grams of astragalus root, 150 to 160 grams of sophora flavescens, 100 to 300 grams of peony bark, 200 to 250 grams of zedoary, 100 to 250 grams of field thistle, 100 to 150 grams of hedyotis diffusa and 250 to 300 grams of honeysuckle. The Chinese medicament is high in stability; and through 96 cases of clinical tests of chronic nephritis patients, the Chinese medicament is exact in treatment effect, and the clinical cure rate of glomerulonephritis or anaphylactic purpura nephritis reaches 68.4 percent.
Owner:管祖臣
Medical application of caper or caper extract
ActiveCN109303790AImprove protectionSignificant ethyl acetate extract effectOrganic active ingredientsAntimycoticsLeprosyGN - Glomerulonephritis
The invention relates to a medical application of caper or caper extract, and specifically provides an application of the caper or caper extract in preparing a medicine or health care product for reducing hepatotoxicity of common threewingnut root, tripterygium glycosides or triptolide, and also provides a composition and an application thereof in preparing a medicine or health care product for preventing and treating rheumatic arthritis, glomerulonephritis, nephrotic syndrome, lupus erythematosus, Sjogren's syndrome, Behcet disease, eczema, psoriasis, leprosy, scabies, stubborn dermatitis, Hashimoto's thyroiditis or tumor, wherein the composition is prepared from a component i) and a component ii), wherein the component i) is caper or caper extract; the component ii) is tripterygium glycosides or triptolide.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Antrodia camphorata and ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney functionmposition
ActiveUS20170224752A1Inhibit renal cancer cell growthImprove kidney functionOrganic active ingredientsFungi medical ingredientsGN - GlomerulonephritisHigh dosage
The present invention provides an Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function. This navel composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering low-dosage Antrodia camphorata and Ganoderma lucidum composition of 7 mg / day / kg to the patient for 20 days. Moreover, because the cell biological experiments have proved that the Antrodia camphorata and Ganoderma lucidum composition of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.
Owner:TAIPEI MEDICAL UNIV
Pharmaceutical composition of dexibuprofen and medicinal use thereof
InactiveCN106008550AHas therapeutic effectOrganic active ingredientsOrganic chemistryNatural productGN - Glomerulonephritis
The invention discloses a pharmaceutical composition of dexibuprofen and its medical use. The pharmaceutical composition of dexibuprofen provided by the invention contains dexibuprofen and a natural product compound (I) with a novel structure. When dexibuprofen and compound (I) act alone, they have a therapeutic effect on glomerulonephritis; when dexibuprofen and compound (I) act in combination, the therapeutic effect is further improved, and can be developed into a drug for treating glomerulonephritis , compared with the prior art, has outstanding substantive features and remarkable progress.
Owner:王昌荣
Chinese medicinal composition for chronic primary glomerulonephritis and its preparation and quality control
InactiveCN1264531CImprove clinical symptomsLower blood creatinineUrinary disorderMaterial impedanceDrugTripterygium wilfordii
A Chinese medicine for treating chronic or primary glomerular nephritis is prepared from 5 Chinese-medicinal materials including astragalus root, Tripterygium wilfordii, dogwood fruit, liquorice root, etc through decocting and / or extracting in alcohol. Its quality control method is also disclosed. Its advantages are high curative effect and no toxic by-effect.
Owner:JIANGSU KANION PHARMA CO LTD
Medicine composition for treating phlegm-damp internal-congestion type latent glomerulonephritis
InactiveCN105596753AControl disease progressionImprove clinical symptomsFungi medical ingredientsUrinary disorderAralia elataOyster
The invention belongs to the technical field of medicines, and particularly relates to a medicine composition for treating the phlegm-damp internal-congestion type latent glomerulonephritis. The medicine composition is prepared from, by weight, 4-8 parts of ternate-leaved rabdosia, 4-8 parts of textile screw pine seeds, 4-8 parts of CerastiumrvenseL., 4-8 parts of rhizome of largeleaf curculigo, 4-8 parts of Pecteilis susannae(L.)Rafin., 4-8 parts of oyster-cap fungi, 4-8 parts of dysosma majorensis(gagnep.)ying, 4-8 parts of balanophora polyandra griff., 4-8 parts of aralia elata, 4-8 parts of rattlesnake plantain, 4-8 parts of melothria heterophylla, 4-8 parts of Crossostephium chinense (L.) Makino ex Cham.et Schltr., 4-8 parts of cortex moutan, 4-8 parts of rhizoma alismatis and 4-8 parts of liquorice roots. The medicines are used in cooperation for achieving the functions of nourishing yin and tonifying yang, and relieving phlegm and dampness. The clinical symptoms of patients suffering from the latent glomerulonephritis can be effectively relieved, the number of urine erythrocyte and the quantitative level of urine protein in 24 hours can be decreased, and the glomerular filtration rate can be increased.
Owner:JINAN BANGWEN MEDICAL TECH
Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
InactiveUS20200018750A1Impact functionImpact survivalImmunoglobulins against cell receptors/antigens/surface-determinantsMaterial analysisDiseaseSegmental glomerulosclerosis
Provided herein are methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis and oilier proteinuric renal diseases such as native FSGS, minimal change disease, glomerular nephritis, membrano-proliferative glomerular nephritis (membranous), or IgA glomerular nephritis (membranous).
Owner:SARWAL MINNIE
Compositions and methods for diagnosing and treating kidney disorders in a canine
ActiveUS9476868B2Reduce probabilityMicrobiological testing/measurementDisease diagnosisFiltrationDecreased glomerular filtration rate
Owner:HILLS PET NUTRITION INC
Pharmaceutical compound preparation for treating glomerulonephritis
InactiveCN107583032AEasy to takeEasy to useAntibacterial agentsOrganic active ingredientsMedicineDrug carrier
The invention discloses a pharmaceutical compound preparation for treating glomerulonephritis. The compound preparation comprises the following components in parts by weight: 10 to 300 parts of nitrofurantoin, 10 to 120 parts of vancomycin, and 10 to 1600 parts of drug carrier. Nitrofurantoin and vancomycin are taken as the pharmaceutical components and mixed with the drug carrier to prepare the compound preparation. The compound preparation is convenient to take, is very safe, has a prominent effect, can greatly reduce complications, generates few sequelae, barely causes adverse reactions, and promotes the healing.
Owner:CHENGDU LINGXI SHANGPIN TECH CO LTD
Traditional Chinese medicine for the treatment of exogenous wind-heat glomerulonephritis with hematuria
InactiveCN104127752BAdjustable serum copper/zinc ratioImprove immunityUnknown materialsUrinary disorderGN - GlomerulonephritisScrophularia
Owner:王祥生
Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol
InactiveUS20110251219A1Effective oral treatmentUse agentOrganic active ingredientsBiocideRenal glomerulusGN - Glomerulonephritis
A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed.
![Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol](https://images-eureka.patsnap.com/patent_img/26da0672-7b4c-4fab-92cc-1174fadec682/US20110251219A1-20111013-D00000.png "Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol")
![Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol](https://images-eureka.patsnap.com/patent_img/26da0672-7b4c-4fab-92cc-1174fadec682/US20110251219A1-20111013-D00001.png "Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol")
![Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol](https://images-eureka.patsnap.com/patent_img/26da0672-7b4c-4fab-92cc-1174fadec682/US20110251219A1-20111013-C00001.png "Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol")
Owner:SANOFI SA
Use of compounds from Antrodia camphorata in manufacturing medicaments for treating kidney diseases
Owner:TSENG HUI LING
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com